Cargando…
Management of hepatitis B in the era of checkpoint inhibition
Hepatitis B virus (HBV) is a major global health concern, affecting more than 350 million people worldwide. Its management in the setting of cancer treatment can be problematic, particularly with the use of immunological treatment modalities, but also with chemotherapy. Immunological perturbations b...
Autor principal: | Dutcher, Janice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057540/ https://www.ncbi.nlm.nih.gov/pubmed/32051288 http://dx.doi.org/10.1136/jitc-2019-000276 |
Ejemplares similares
-
Resistance to systemic immune checkpoint inhibition in the peritoneal niche
por: Chia, Daryl Kai Ann, et al.
Publicado: (2022) -
Hepatitis C in the criminal justice system: opportunities for global action in the era of viral hepatitis elimination
por: Akiyama, Matthew J.
Publicado: (2020) -
Abscission checkpoint control: stuck in the middle with Aurora B
por: Carmena, Mar
Publicado: (2012) -
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
por: Symeonides, Stefan N., et al.
Publicado: (2017) -
Running on a treadmill: dynamic inhibition of APC/C by the spindle checkpoint
por: Díaz-Martínez, Laura A, et al.
Publicado: (2007)